Navigation Links
Amira Pharmaceuticals Hits Two Development Milestones Related to FLAP Inhibitor Program

SAN DIEGO, July 19 /PRNewswire/ -- "Amira Pharmaceuticals, Inc. announced today that its FLAP (5-lipoxygenase-activating protein) program, which is partnered with GlaxoSmithKline, has achieved two clinical development milestones."

These milestones are related to the successful progression of the program to Phase 2 studies, which explore the use of the Amira discovered FLAP inhibitor in patients suffering from asthma.  

"These milestones demonstrate the success of our partnership with GSK as well as the need for new therapies for asthma sufferers." said Hari Kumar, Chief Business Officer.  "These milestone payments enable Amira to continue to fund our highly productive research and development opportunities well into the future."

About FLAP Inhibitors

FLAP (5-lipoxygenase-activating protein) is a key component early in the leukotriene pathway, a complex signalling process that exerts control over biological processes, such as inflammation and immunity. Excessive production of leukotrienes exacerbates inflammatory diseases, such as asthma; the FLAP gene has also been linked to a significant increase in the risk of myocardial infarction and stroke. AM103 and AM803, Amira's FLAP inhibitors licensed to GSK, bind to FLAP thereby inhibiting the synthesis of leukotrienes that cause inflammation.

About Amira

Founded in 2005 and headquartered in San Diego, Amira Pharmaceuticals is a small molecule pharmaceutical company focused on the discovery and early development of new drugs to treat inflammatory disease. Our discovery team is building on unparalleled insights into bioactive lipid pathways and complex signaling processes controlling many conditions including asthma, chronic obstructive pulmonary disease, cardiovascular and fibrotic diseases. Amira has a partnership with GlaxoSmithKline for the development of FLAP (5-lipoxygenase-activating protein) inhibitors in respiratory and cardiovascular disease. Amira combines the rigor of a big pharmaceutical company with the ingenuity and energy of a small company, creating an environment for efficient development of novel compounds and effective pre-clinical and clinical program decisions. Its scientific founders have successfully worked together for more than a decade and were pivotal in the discovery of a number of inflammatory drugs, including Singulair®. The drug hunters at Amira are now actively leveraging their history of success to create high-value compounds for the future.  For more information, visit

SOURCE Amira Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Amira Initiates Phase I Clinical Trial of Novel DP2 Antagonist
2. Amira Pharmaceuticals to Present at the 28th Annual J.P. Morgan Healthcare Conference
3. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2008 Financial Results on Monday, August 11, at 8:30 A.M. EDT
4. ISTA Pharmaceuticals Reports Second Quarter 2008 Financial Results
5. SGX Pharmaceuticals Announces Financial Results for the Three and Six Months Ended June 30, 2008
6. ADVENTRX Pharmaceuticals to Report Second Quarter 2008 Results
7. Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1 Study of MM-121, an ErbB3 Antagonist
8. VIA Pharmaceuticals to Present at Fourth Annual Noble Financial Equity Conference
9. Anthera Pharmaceuticals Completes $19 Million Financing; Appoints Christopher S. Henney as Chairman
10. Access Pharmaceuticals to Present at the Noble Financial Equity Conference
11. Indevus Pharmaceuticals Announces Issuance of U.S. Patent for SANCTURA XR(TM)
Post Your Comments:
(Date:11/24/2015)... /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ:  AEZS) (TSX: ... 11,000 post-share consolidation (or 1,100,000 pre-share consolidation) Series ... Warrants") subject to the previously disclosed November 1, ... which will result in the issuance of 365,518 ... issuance of such shares, there will be approximately ...
(Date:11/24/2015)... ... November 24, 2015 , ... ... are paramount. Insertion points for in-line sensors can represent a weak spot where ... InTrac 781/784 series of retractable sensor housings , which are designed to tolerate ...
(Date:11/24/2015)... Vancouver, BC (PRWEB) , ... November 24, 2015 ... ... to our customer, OrthoAccel® Technologies, Inc., on being named to Deloitte's 2015 Technology ... Creation Technologies’ Texas facility, OrthoAccel manufactures AcceleDent®, a FDA-cleared, Class II medical device ...
(Date:11/24/2015)... ANGELES , Nov. 24, 2015 ... biotechnology company focused on the discovery, development and commercialization ... , Ph.D., Chief Executive Officer, is scheduled to present ... 1, 2015 at 10:50 a.m. EST, at The Lotte ... City . . ...
Breaking Biology Technology:
(Date:10/29/2015)... October 29, 2015 NXTD ... company focused on the growing mobile commerce market ... that StackCommerce, a leading marketplace to discover and ... Wocket® smart wallet on StackSocial for this holiday ... or the "Company"), a biometric authentication company focused ...
(Date:10/27/2015)... 2015 In the present market scenario, security ... various industry verticals such as banking, healthcare, defense, electronic ... demand for secure & simplified access control and growing ... hacking of bank accounts, misuse of users, , and ... PC,s, laptops, and smartphones are expected to provide potential ...
(Date:10/27/2015)... 2015 Synaptics Inc. (NASDAQ: SYNA ), the ... has adopted the Synaptics ® ClearPad ® ... its newest flagship smartphones, the Nexus 5X by LG ... --> --> Synaptics works closely ... collaboration in the joint development of next generation technologies. ...
Breaking Biology News(10 mins):